In the literature, the epidemiological pattern of ovarian neoplasms in different age groups in the Almadinah Almunawwarah region in KSA has not been completely elucidated. Moreover, an unusually frequent diagnosis of adult granulosa cell tumour (AGCT) has been observed in patients in Almadinah Almunawwarah, KSA. This study aimed to describe the pattern of ovarian neoplasms in different age groups in the Almadinah Almunawwarah region with particular emphasis on AGCT. Histopathological records of all ovarian specimens diagnosed from 2011 January to 2016 December were collected from the Maternity and Children Hospital in Almaadinah Almunawwarah, KSA. Hematoxylin and eosin (HE)-stained microscopic slides of serous and mucinous epithelial borderline neoplasms and of malignant epithelial, sex cord-stromal and germ line neoplasms were identified and examined. The tissue sections from the AGCT were stained immunohistochemically with BRCA-1 antibody. A total of 301 ovarian specimens were obtained. Of the specimens, 217 (72%) were neoplastic and 84 (28%) were non-neoplastic. In total, 135 (63%) of the neoplastic specimens were benign, 16 (7%) were borderline tumours, and 66 (30%) were malignant tumours. Moreover, 41 (62%) of the malignant tumours were surface epithelial carcinomas, 17 (26%) were sex cord-stromal tumours, and 8 (12%) were germ cell tumours. The incidence of AGCT was unusually high, which accounts for 26% (16/66) of all malignant ovarian neoplasms. Altered BRCA-1 expression was observed in only two specimens. In this study, malignant ovarian neoplasms accounted for 30% of all neoplastic ovarian specimens, and the incidence of AGCT was remarkable. Such tumours did not show a significantly altered expression of BRCA-1. Further studies must be conducted to explore the underlying molecular causes of this condition.
Vascular invasion (VI) is an essential step in the progression of breast cancer (BC) and is a key factor behind morbidity and mortality. In a previous work using gene expression profiling, upregulation of STYK1 was one of the genetic changes that was found associated with VI. The aims of the following study were to assess (1) level and pattern of STYK1 expression in BC tissues and (2) its association with clinicopathological features and with patient outcome. Histopathological, clinical data and 10‒year survival data for 220 primary breast carcinoma was retrieved. From each specimen, one representative formalin-fixed paraffin-embedded tissue section was stained by immunohistochemistry (IHC) with STYK1 antibodies. IHC score was calculated and correlated with clinicopathological features of tumors. Higher STYK1 expression was detected in invasive BC compared with normal and non-invasive tumors, P = 0.001 and was significantly associated with the presence of vascular invasion (P = <0.001), lymph node metastasis (P = 0.032) estrogen receptor positivity (P = 0.033), non‒triple negative phenotype (P = <0.018) and occurrence of locoregional recurrence (P = 0.011). No association was detected with other tumor features such as tumor size, grade, development of distant metastasis or overall survival. STYK1 is expressed at a higher level in invasive BC compared with non-cancerous tissues. This high expression is significantly associated with presence of VI, LN metastasis and occurrence of recurrence. These findings suggest that STYK1 could be a possible molecular target for breast carcinoma. Targeted therapy that can inhibit STYK1 kinase can be a possible approach for the development of novel therapies in breast carcinoma.
Background: PAPSS1 (3′-Phosphoadenosine 5′-Phosphosulfate Synthase 1) plays a central role in the sulfation process that regulates estrogen activity; however, its pattern of expression and association with clinicopathological features in breast carcinoma (BC) are not fully examined. Methods: A total of 150 BC specimens with clinicopathological and 10-year follow-up data were analyzed. PAPSS1 protein expression was assessed using immunohistochemistry (IHC) and correlated with clinicopathological parameters and patient outcome. Transcriptomic and promotor methylation analyses were performed using TCGA-BRCA through UALCAN. Proteomic data was evaluated using the CPTAC dataset, and the gene interaction network was analyzed using STRING. Results: IHC demonstrated significantly higher PAPSS1 expression in invasive carcinomas compared with non-invasive carcinoma and with normal mammary acini (p < 0.0001). High expression was associated with the presence of vascular invasion (VI) (p = 0.003), LN metastasis (p = 0.008), and higher PAPSS1 expression in tumor capillaries (p < 0.001). CPTAC analyses confirmed significantly elevated PAPSS1 in tumors versus normal tissues (p < 0.0001), particularly in stage II and III tumors, triple-negative BC, and basal stromal-related molecular subtypes. The transcriptomic data showed different expression patterns according to tissue type; it is higher in GIT tumors. The opposite was found in lung and pancreatic carcinoma. In BC, transcriptional expression was not different between normal and tumors; it was lower in higher nodal stages and highest in medullary carcinoma and in TP53-mutant tumors. Conclusions: PAPSS1 is overexpressed in BC and is associated with VI, LN metastasis, and tumor progression, suggesting a potential role in BC aggressiveness. Further studies are recommended to explore its mechanistic role.